Completed
A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)
NCT00000775
- Conditions
- Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
- Locations
-
- St Louis Univ School of Medicine St Louis, Missouri, United States
- Univ of Rochester Med Ctr Rochester, New York, United States